Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products.

READ MORE

Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer READ MORE DATE: August 25, 2020 Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer READ MORE DATE: July 15, 2020 Precision Biologics and the National Cancer Institute deliver 2 Poster Presentations at the AACR virtual meeting June 22-24th, 2020 READ MORE DATE: June 22, 2020 Results of Precision Biologics Phase 2 Colorectal Cancer Study Published in Clinical Cancer Research READ MORE DATE: April 30, 2020 Indirect mechanisms of action of a novel IgG1 monoclonal antibody, NEO-201, that enhance immune killing of tumor READ MORE DATE: February 7, 2020 Phase 1 with Expansion Cohorts in a Study of NEO-201 in Adults with Chemo-Resistant Solid tumors READ MORE DATE: January 23, 2020
0
# of people living with cancer in the US
0
annual # of new cases of cancer in the US
0
annual # of deaths from cancer in the US

Discover our innovative Leaders.

Meet our Team

News and Events

Latest News

VIEW MORE